Interstitial lung disease in 2015: where are we now?
BACKGROUND
Interstitial lung disease (ILD) includes a diverse group of respiratory conditions characterised by inflammation and fibrosis of the interstitium. Worsening hypoxia and respiratory failure may develop with disease progression. Disease behaviour and treatment responsiveness vary widely depending on the underlying aetiology. One of the most common types of ILD is idiopathic pulmonary fibrosis (IPF), which is associated with poor prognosis.


OBJECTIVE
This article discusses recent advances in the field of ILD, including updated classification, diagnostic approach and break-through therapies.


CONCLUSIONS
Establishing an accurate diagnosis in patients with ILD, ideally within a multidisciplinary team discussion, is critical for ensuring optimal outcomes. Recently, novel antifibrotic therapies have been shown to be effective in slowing disease progression in IPF, offering new hope for patients with the disease.
MBBS, BMedSci, FRACP, Respiratory Staff Specialist, Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW; Sydney Medical School, University of Sydney, NSW.
Lauren
L
Troy
Tamera
T
Corte
D000368:Aged; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000145:classification / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D012907:Smoking / Q000009:adverse effects